Shots:

• The P-III EXPEDITION Study involves assessing of Solanezumab (400 mg- IV- q4w) vs PBO in 1-012 (EXPEDITION1) & 1-040 (EXPEDITION2) patients with mild or mild to moderate Alzheimer disease
• The study resulted in unmet endpoint and demonstrated 42% reduction in decline- 20% reduction in cognitive decline- 19 percent reduction in functional decline in patients
• Solanezumab is a monoclonal IgG1 Ab- evaluated as a neuroprotector in patients with Alzheimer disease

Ref: Eli Lilly | Image: The Street